

**Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up**

<b>Rs. Mio.</b>	<b>Q2 16-17</b>	<b>Q2 15-16</b>	<b>% Gr y-y</b>	<b>YTD 16-17</b>	<b>YTD 15-16</b>	<b>% Gr y-y</b>
<b>Formulations Business - Key Markets</b>	<b>19,883</b>	<b>19,275</b>	<b>3.2%</b>	<b>38,091</b>	<b>38,319</b>	<b>-0.6%</b>
US Formulations	9,888	10,038	-1.5%	18,371	19,888	-7.6%
India Formulations	8,209	7,543	8.8%	16,071	14,938	7.6%
Latin America Formulations	656	527	24.6%	1,183	1,080	9.6%
Emerging Markets Formulations	1,130	1,167	-3.2%	2,466	2,412	2.2%
<b>Other Businesses and Alliances</b>	<b>3,985</b>	<b>3,831</b>	<b>4.0%</b>	<b>8,401</b>	<b>7,892</b>	<b>6.4%</b>
Europe Formulations	557	649	-14.1%	1,349	1,484	-9.1%
Consumer Wellness	1,119	1,040	7.6%	2,280	2,075	9.9%
Animal Health & Others	1,225	806	51.9%	2,322	1,569	48.0%
APIs	832	898	-7.4%	1,808	1,886	-4.2%
Alliances	252	438	-42.5%	642	877	-26.8%
<b>Grand Total</b>	<b>23,868</b>	<b>23,106</b>	<b>3.3%</b>	<b>46,491</b>	<b>46,211</b>	<b>0.6%</b>

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q2 16-17	Q2 15-16	% Gr y-y	YTD 16-17	YTD 15-16	% Gr y-y
<b>Other Operating Income</b>	<b>168</b>	<b>844</b>	<b>-80.0%</b>	<b>875</b>	<b>1,999</b>	<b>-56.2%</b>
Export Incentive	180	306	-41.1%	467	532	-12.2%
Royalty Income	19	62	-68.6%	50	101	-50.7%
Net Gain on foreign currency transactions and translation (Refer Note below)	-144	124	-216.8%	87	186	-53.4%
Others	113	352	-67.9%	272	1,180	-77.0%

Note : There was a net loss of Rs. 120 Mio. on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods in Q2 16-17. Thus, on aggregate level, there was a loss of Rs. 264 Mio. on operating transactions (above EBIDTA line) in Q2 16-17 vs gain of Rs. 290 Mio. in Q2 15-16. See details below for more clarity.

Rs. Mio.	Q2 16-17	Q2 15-16	% Gr y-y	YTD 16-17	YTD 15-16	% Gr y-y
<b>Other Income</b>	<b>236</b>	<b>199</b>	<b>18.6%</b>	<b>389</b>	<b>440</b>	<b>-11.6%</b>
Interest & Dividend income	181	163	10.5%	301	306	-1.7%
Profit on sale of investments	21	16	30.7%	52	49	6.1%
Others	35	20	74.9%	36	85	-57.8%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q2 16-17	Q2 15-16	% Gr y-y	YTD 16-17	YTD 15-16	% Gr y-y
<b>A. On operating transactions (above EBIDTA line)</b>	<b>264</b>	<b>-290</b>	<b>191.0%</b>	<b>-204</b>	<b>-484</b>	<b>57.9%</b>
a. Included in other income	144	-124	216.1%	-87	-186	53.2%
b. Included in cost of goods	120	-166	172.3%	-117	-298	60.7%
<b>B. On Foreign Currency Borrowings (part of interest cost)</b>	<b>19</b>	<b>24</b>	<b>-20.8%</b>	<b>37</b>	<b>29</b>	<b>27.6%</b>
<b>Total Foreign Currency Fluctuations (+ = loss, - = gain)</b>	<b>283</b>	<b>-266</b>	<b>206.4%</b>	<b>-167</b>	<b>-455</b>	<b>63.3%</b>

Details of R&D Expenses

Rs. Mio.	Q2 16-17	Q2 15-16	% Gr y-y	YTD 16-17	YTD 15-16	% Gr y-y
<b>Total R&amp;D Expenses</b>	<b>1,529</b>	<b>1,730</b>	<b>-11.6%</b>	<b>3,149</b>	<b>3,414</b>	<b>-7.8%</b>

Consolidated Capex for H1 FY17

Rs. 7022  
Mio.

R&D capex included in above for H1 FY17

Rs. 127  
Mio.